Kyverna Therapeutics, Inc.KYTXNASDAQ

Revenue (LTM)

Net Income (LTM)

$-127M

-111.2% YoY

Free Cash Flow

$-116M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24
Revenue	6	7↑24.2%	0	0
Gross Profit	6	7↑24.2%	-2↓124.3%	-2↓25.0%
Operating Income	-26	-29↓11.5%	-62↓112.4%	-143↓128.5%
Net Income	-26	-29↓9.7%	-60↓108.9%	-127↓111.2%
EBITDA	-26	-28↓7.8%	-58↓110.5%	-125↓114.1%
EPS Diluted	-1.02	-1.12↓9.8%	-0.00↑100.0%	-3.33↓3329900.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24
Cash & Equivalents	76	38↓50.4%	35↓8.2%	97↑178.9%
Total Current Assets	77	53↓30.9%	61↑13.9%	291↑379.0%
Total Assets	85	67↓21.7%	75↑12.4%	305↑305.1%
Total Current Liabilities	16	12↓24.9%	20↑66.1%	34↑70.0%
Total Liabilities	132	20↓84.6%	26↑28.5%	38↑46.3%
Total Equity	-46	47↑200.9%	49↑5.4%	267↑442.1%
Total Debt	6	11↑90.2%	9↓14.1%	8↓9.2%
Net Debt	-71	-27↑61.5%	-26↑5.9%	-88↓245.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24
Operating Cash Flow	-22	-36↓63.0%	-52↓45.1%	-114↓118.0%
Capital Expenditure	-1	-1↑40.4%	-1↑19.1%	-2↓255.1%
Free Cash Flow	-23	-37↓57.3%	-53↓43.8%	-116↓119.6%
Stock-Based Comp	7	1↓87.2%	2↑139.0%	8↑276.4%
Net Change in Cash	49	-38↓178.1%	-3↑92.0%	62↑2113.7%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance